糖尿病黄斑水肿患者行醋酸氟轻松治疗规范:2023年专家共识解读  

Specification on the fluocinolone acetonide treatment for patients with diabetic macular edema:interpretation of expert consensus 2023

作　　者：邵毅 葛倩敏 陈序 SHAO Yi;GE Qianmin;CHEN Xu(Eye&ENT Hospital of Fudan University,Shanghai 200031,China;Department of Ophthalmology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi Province,China;Ophthalmology Centre of Maastricht University,Maastricht 6200MS,Limburg Province,Netherlands)

机构地区：[1]复旦大学附属眼耳鼻喉科医院,上海市200031 [2]南昌大学第一附属医院眼科,江西省南昌市330006 [3]马斯特里赫特大学眼科中心,荷兰林堡省马斯特里赫特市6200MS

出　　处：《眼科新进展》2023年第10期757-760,共4页Recent Advances in Ophthalmology

基　　金：国家自然科学基金项目(编号:82160195);中央引导地方科技发展资金项目(编号:20211ZDG02003)。

摘　　要：为了更好地了解视网膜病专家对于炎症在糖尿病视网膜病变(DR)和糖尿病黄斑水肿(DME)中所起作用的一致程度,以及使用0.19 mg醋酸氟轻松(FAc)玻璃体内注射治疗DME的效果认同情况,起草了一份共识调查报告,共有56名美国视网膜病专家完成了整个共识调查。医生高度同意炎症在DR/DME的病理生理学、注射负荷和患者依从性、FAc玻璃体内注射的有效性和安全性方面的作用。然而,对于FAc植入剂对DR进展的影响、FAc作为DME的基线治疗以及类固醇刺激降低FAc使用后眼压风险的有效性,尚未达成共识。本文就该专家共识进行解读,为FAc玻璃体内注射治疗DR/DME方案的进一步研究和应用提供参考。To better understand the consistency in the role of inflammation in diabetic retinopathy(DR)and diabetic macular edema(DME)and the efficacy of injecting 0.19 mg fluocinolone acetonide(FAc)intravitreally to treat DME,a consensus survey report was drafted by 56 retinal disease experts from the United States.Doctors highly agreed on the role of inflammation in DR/DME pathophysiology,injection loading and patient compliance,as well as the efficacy and safety of FAc injections.However,no consensus has been established on the effect of FAc implants on DR progression,the efficacy of FAc as a baseline treatment for DME,and the effectiveness of steroid stimulation to reduce the risk of intraocular pressure after FAc use.This paper interprets the expert consensus,providing references for further research and application of FAc injections for DR/DME treatment.

关 键 词：醋酸氟轻松 糖尿病视网膜病变 糖尿病黄斑水肿 治疗 共识 

分 类 号：R777.31[医药卫生—眼科]